Kane Biotech Secures Large Order from Leading Quebec Retailer
WINNIPEG, Manitoba, June 25, 2019 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE), (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced that it has secured a major order for its bluestem product line from Mondou, a leader in the distribution of products, services, and accessories for the health and well-being of pets in Quebec.
Marc Edwards, Chief Executive Officer, stated, “I am thrilled to be working with Mondou to grow our presence in Quebec. Mondou is a North American model of excellence in the pet retail space and securing a significant order from them validates the high quality of our products.”
Mondou currently operates 68 brick and mortar stores as well as a major distribution center. They also have an online retail presence. In addition to taking in the entire bluestem line, the Quebec retailer has requested that Kane expand their line of toothpastes in order to meet the needs of their growing customer base.
The order will also be supported by an extensive marketing campaign led by both companies, which will include discounted pricing, employee training, in-store marketing and digital marketing. In addition, Kane will be showcasing their products at the “Rendez-vous Mondou – Festival Canin”, a unique event with more than 10,000 dog owners expected to attend.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Corporation has a portfolio of biotechnologies, intellectual property (58 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions. StrixNB(TM), DispersinB(R), Aledex(R), bluestem(TM), AloSera(TM), coactiv+(TM) and Kane(R) are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol "KNE".
For more information, please visit www.kanebiotech.com, or contact:
|Chief Executive Officer|
|Kane Biotech Inc.|
|+1 (514) firstname.lastname@example.org|
|US. Investor Relations|
|+1 (646) email@example.com|
|US. Investor Relations|
|+1 (646) 653 firstname.lastname@example.org|
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar.com. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
Released June 25, 2019